If approved, clesrovimab has the potential to be available to help address the burden of RSV disease in the U.S. in time for the 2025-26 season “Despite recent advances in RSV prevention, unmet needs ...
If approved, clesrovimab has the potential to be available to help address the burden of RSV disease in the U.S. in time for the 2025-26 season RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback